CDA抗体—艾普蒂

+ +

•  

   

     Gel: 12%SDS-PAGE, Lysate: 40 μg, Lane: LO2 cell lysate, Primary antibody: P09460(CDA Antibody) at dilution 1/1000, Secondary antibody: Goat anti rabbit IgG at 1/5000 dilution, Exposure time: 10 seconds    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human breast cancer tissue using P09460(CDA Antibody) at dilution 1/100. (Original magnification: ×200)    

  
  

•  

   

     The image is immunohistochemistry of paraffin-embedded Human esophagus cancer tissue using P09460(CDA Antibody) at dilution 1/100. (Original magnification: ×200)    

  
  

Cytidine deaminase (CDA) antibodies are immunological tools designed to target enzymes involved in nucleotide metabolism, particularly cytidine deaminases. These enzymes, such as activation-induced deaminase (AID) and APOBEC (apolipoprotein B mRNA editing enzyme catalytic polypeptide-like) family members, play critical roles in DNA/RNA editing, immune response regulation, and antiviral defense. For instance, AID is essential for antibody diversification via somatic hypermutation, while APOBEC enzymes restrict viral replication by introducing mutations in viral genomes. Dysregulation of CDA activity is linked to cancer, autoimmune disorders, and viral persistence, making these enzymes key research targets.

CDA antibodies are widely used to study enzyme expression, localization, and function in both physiological and pathological contexts. In cancer research, they help assess CDA levels in tumors, which may influence chemotherapeutic drug resistance (e.g., gemcitabine sensitivity). In virology, they aid in understanding host-pathogen interactions, particularly HIV evasion mechanisms against APOBEC3G. Structurally, these antibodies often recognize conserved epitopes within the zinc-binding catalytic domains of CDA enzymes, enabling applications like Western blotting, immunohistochemistry, and flow cytometry.

Therapeutic development also leverages CDA antibodies to modulate enzyme activity, such as inhibiting CDA to enhance chemotherapy efficacy. Challenges include ensuring specificity due to homology among deaminase family members. Overall, CDA antibodies serve as vital reagents in deciphering nucleotide-editing mechanisms and their implications in disease.